Back to Search Start Over

Therapeutic innovations in breast cancer.

Authors :
Le Du F
Perrin C
Brunot A
Crouzet L
De La Motte Rouge T
Lefeuvre-Plesse C
Dieras V
Source :
Presse medicale (Paris, France : 1983) [Presse Med] 2019 Oct; Vol. 48 (10), pp. 1131-1137. Date of Electronic Publication: 2019 May 29.
Publication Year :
2019

Abstract

Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. New antibodies drug conjugates for HER2+ and TNBC. Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation. Immunotherapies in 1st line metastatic setting of TNBC.<br /> (Copyright © 2019. Published by Elsevier Masson SAS.)

Subjects

Subjects :
Breast Neoplasms chemistry
Cyclin-Dependent Kinase 4 antagonists & inhibitors
Cyclin-Dependent Kinase 6 antagonists & inhibitors
Female
Humans
Immunoconjugates therapeutic use
Immunotherapy methods
Poly(ADP-ribose) Polymerase Inhibitors therapeutic use
Protein Kinase Inhibitors therapeutic use
Randomized Controlled Trials as Topic
Breast Neoplasms therapy

Details

Language :
English
ISSN :
2213-0276
Volume :
48
Issue :
10
Database :
MEDLINE
Journal :
Presse medicale (Paris, France : 1983)
Publication Type :
Academic Journal
Accession number :
31151842
Full Text :
https://doi.org/10.1016/j.lpm.2019.04.005
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details